Navigation Links
BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
Date:10/27/2008

EXTON, Pa., Oct. 27 /PRNewswire/ -- BioTrends Research Group, Inc. released two new Nephrology TreatmentTrends(TM) publications based on survey results from 204 Nephrologists and 201 Renal Dietitians in the US. Renal Dietitians (RDs) are an integral part of the management of dialysis patients, particularly in their role recommending and reinforcing adherence with Phosphate Binders, Active Vitamin D, and Calcimimetic agents.

In the phosphate binder market, the introduction of Genzyme's Renvela has given overall sevelamer share a boost compared to the same quarter last year, although most of the patients on Renvela have been switched from Renagel. Close to two-thirds of MDs and over three quarters of RDs have used Renvela in their hemodialysis patients, however, Renagel and FMC's PhosLo remain the two most frequently prescribed binders among dialysis patients. While sevelamer has the highest share across all types of dialysis units, Shire's Fosrenol does its best in Davita units whereas PhosLo does its best in Fresenius units. Nephrologists are divided as to their first line preference in dialysis -- approximately half choose a calcium-based binder and half choose a non-calcium based binder compared to over two-thirds of RDs who choose to start with a non-calcium based binder. In patients with Chronic Kidney Disease not on dialysis (CKD), 73% of Nephrologists prefer to start with calcium-based binders.

In the PTH modifier market, although RDs report a high level of influence in the choice of Vitamin D, approximately 80% report that their dialysis center generally encourages the use of Abbott's Zemplar, compared to only 29% who report they are encouraged to use Genzyme's Hectorol. While Zemplar IV is the overwhelming market share leader in hemodialysis and leads in every type of dialysis unit, Hectorol does its best in non-chains and its worst in Davita. In CKD, Nephrologists continue to use oral calcitriol most often. Compared to the prior year, R
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioTrends Research Group, Inc. Recognized as One of Philadelphias Fastest Growing Privately Held Companies
2. New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
3. BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
4. New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists
5. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
6. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
7. T-System Releases The T SystemEV(R) 2.6.3, Featuring New Meds/Allergies Notification, Automated Charge Capture
8. BioWisdom Releases Text Analytics Version of OmniViz for Patent Specialists
9. Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009
10. Presidio Pay Advisors Releases Salary GPS Tool
11. Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Oct 24, 2014 Research and Markets ... Market by Product , Research Area & by End ... their offering. In this report, the ... products, research areas, and end users. The product segments ... enzymes, instruments & consumables, kits, and reagents. The subsegments ...
(Date:10/22/2014)... October 21, 2014 The Americas ... inorganic refrigerants market in Americas with analysis and ... of the Americas Inorganic Refrigerants Market report, to ... This also provides a glimpse of the segmentation ... supported by various tables and figures. , ...
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... next steps for its Oral Amphotericin B program.  ... in vitro work involving samples from ... plans to complete pre clinical studies and regulatory ... 1A clinical trial, utilizing approximately $700,000 of funding ...
Breaking Biology Technology:Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3
... July 10 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... European Medicines Agency (EMEA) for ranolazine for,the treatment of ... (EU),member states. This approval follows a positive opinion from ... on April 24, 2008., Ranolazine is approved for ...
... MADISON, N.J., July 10 Quest Diagnostics,Incorporated (NYSE: ... and services, announced today that its second-quarter,2008 results will ... market,opens, and that it will hold its quarterly conference ... a.m. ET on that day., The public may ...
... Inc. (Nasdaq: ALXN ), today announced that the ... on Tuesday, July 29, 2008, at,10:00 a.m. Eastern Time ... for the second quarter ended June 30, 2008. Alexion,anticipates ... Tuesday,July 29, 2008., To participate in this conference ...
Cached Biology Technology:CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 2CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 3Quest Diagnostics to Release Second Quarter 2008 Financial Results 2
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... Calif. (October 16, 2014) – Post-menopausal women experienced ... on hormone levels or genital bleeding, after 12 ... an investigational fermented soy germ-based nutritional supplement previously ... to a new peer-reviewed pilot study reported in ... (NAMS) annual scientific meeting. , "These data ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... Grand Canyon may be so old that dinosaurs once lumbered ... the University of Colorado at Boulder and the California Institute ... radiometric dating to show the Grand Canyon may have formed ... origins by 40 million to 50 million years. The ...
... researchers is needed to make progress towards one ... marks contribute to regulation of gene expression. This ... European Science Foundation (ESF), Computational Approaches to the ... Epigenetics studies features of the DNA and chromatin ...
... NEW YORK, April 9 e-Smart(R) Technologies,Inc. ... and its parent,company, IVI Smart Technologies, Inc., ... filed in a Motion last month by,IDsmart ... Northern District of,California, San Francisco Division, Case ...
Cached Biology News:Grand Canyon may be as old as dinosaurs, says new study 2Grand Canyon may be as old as dinosaurs, says new study 3Computation to unravel how genes are regulated and shed light on how cells become different 2Computation to unravel how genes are regulated and shed light on how cells become different 3IDsmart Admits in Court Document That e-Smart's Technology was Used to Develop IDsmart's Smart Card 2IDsmart Admits in Court Document That e-Smart's Technology was Used to Develop IDsmart's Smart Card 3
Ephrin A4...
Rad51B...
... Rabbit polyclonal to Ki67 - Proliferation Marker, ... cell cycle related nuclear protein, expressed by ... active cell cycle (G1, S, G2 and ... (G0) cells. Ki67 antibodies are useful in ...
... reactive against the complex IV assembly factor SURF1. ... cultured cells. SURF1 is an important assembly factor ... participate in the folding of subunit II and ... SURF1, particularly ones that result in an absence ...
Biology Products: